Syngene International Q4 FY26: Profit Declines, Margins Under Pressure, Expansion Continues

📊 Financial Performance Net Profit: ₹1.48B vs ₹1.83B YoY (↓19%). Revenue: ₹10.37B vs ₹10.2B YoY (↑2%). EBITDA: ₹3B vs ₹3.44B YoY (↓13%). EBITDA Margin: 29.27% vs 33.75% YoY (margin contraction). 📈 Key Financial Ratios Net Profit Margin: ~14.3% (down from ~17.9% YoY). EBITDA Margin: 29.3% (down from 33.8%). ROE: ~11–12% (impacted by profit decline). ROCE: ~10–11% (reflects weaker capital efficiency). Debt-to-Equity: Very low, Syngene operates with a strong balance sheet. Interest Coverage Ratio: High, minimal debt burden. ✅ Fundamentals Global Pharma Services Leader: Strong presence in contract research, development, and manufacturing. Revenue Growth: Flat, showing resilience despite global pharma headwinds. Profit Decline: Lower margins due to higher costs and pricing pressure. Cash Flow Strength: Debt-light balance sheet provides financial flexibility. Parentage: Backed by Biocon Group, ensuring credibility and client trust. 🏗️ Projects & Expansion Biologics & API Manufacturing: Expanding capabilities in biologics and small molecules. Global Partnerships: Collaborations with leading pharma and biotech companies. Digital Transformation: Investments in automation and AI-driven drug discovery. Capacity Expansion: New labs and manufacturing facilities to support growth. ⚠️ Risks & Challenges Margin Pressure: EBITDA margin contraction due to rising input and compliance costs. Client Concentration: Dependence on large global pharma clients. Regulatory Risks: Strict norms in drug development and manufacturing. Competition: Intense rivalry from other CROs/CDMOs globally. Currency Risks: Export exposure makes earnings sensitive to forex fluctuations.